Recent Development on HIV Variants and HIV Vaccine

Penulis

  • Ridwan Balatif Medical Doctor Profession Program, Faculty of Medicine, University of Sumatera Utara, Medan, Indonesia
  • Fadlan Hafizh Harahap Medical Doctor Profession Program, Faculty of Medicine, University of Sumatera Utara, Medan, Indonesia
  • Isni Dhiyah Almira Medical Doctor Profession Program, Faculty of Medicine, University of Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.55175/cdk.v49i12.328

Kata Kunci:

HIV, vaccines

Abstrak

Human immunodeficiency virus (HIV) is a virus from the Retrovirus family that attacks human immune cells, especially T lymphocytes. The increasing number of HIV cases requires a more effective preventive measure; among others is through vaccination. Although it has been about 40 years, there is no HIV vaccine on the market yet. It can be because of many variations of HIV and each country has its own dominant HIV variant. In addition, the ability of HIV virus to evade immune responses, high mutation rates, and limited experimental animals add to the difficulties to develop effective vaccines. As of May 2022, 16 vaccines are currently undergoing phase I/II clinical trials. Among HIV vaccines that have already undergone phase III clinical trials, only RV 144 vaccine gave promising results, with efficacy reaching 31.2%. The development of the HIV vaccine continues to obtain a safe and effective HIV vaccine.   Human immunodeficiency virus (HIV) merupakan virus dari famili Retrovirus yang menyerang sel imun manusia terutama limfosit T. Kasus infeksi HIV yang terus meningkat, membutuhkan tindakan pencegahan yang lebih efektif antara lain dengan vaksin HIV. Tetapi, meskipun sudah sekitar 40 tahun, belum ada vaksin HIV yang diedarkan. Hal ini bisa karena banyaknya variasi HIV serta tiap negara memiliki varian HIV dominan yang berbeda. Selain itu, kemampuan HIV menghindari respon imun, laju mutasi yang tinggi, ditambah dengan keterbatasan hewan coba, menyulitkan pembuatan vaksin. Hingga bulan Mei 2022 terdapat 16 vaksin yang tengah menjalani uji klinis fase I/II. Di antara vaksin HIV yang sudah pernah menjalani uji klinis fase III, hanya vaksin RV 144 yang memberikan hasil menjanjikan yakni efikasi mencapai 31,2%. Perkembangan vaksin HIV terus berlanjut untuk mendapatkan vaksin HIV yang aman dan efektif.  

 

Unduhan

Data unduhan belum tersedia.

Referensi

Balatif R. HIV Infection: What Should We Know. Jetromi. 2020; 2(1): 1-16. Doi: 10.32734/jetromi.v2i1.2038

HIV Vaccines | What Are Vaccines and What Do They Do? [Internet]. 2022. Available from: https://www.hiv.gov/hiv-basics/hiv-prevention/potential-future-options/hiv-vaccines [accessed 2022 Jul 12]

WHO. HIV/AIDS [Internet]. World Health Organization. 2021. Available from: https://www.who.int/health-topics/hiv-aids#tab=tab_1 [accessed 2022 Jul 13]

Hidayati AN, Rosyid AN, Nugroho CW, Asmarawati TP, Ardhiansyah AO, Bakhtiar A, et al. Manajemen HIV/AIDS: Terkini, Komprehensif, dan Multidisiplin. Surabaya: Airlangga University Press; 2019.

UNAIDS. Global HIV & AIDS statistics — Fact sheet [Internet]. UNAIDS. 2021. Available from: https://www.unaids.org/en/resources/fact-sheet [accessed 2022 Jul 13]

Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. Laporan Perkembangan HIV AIDS dan Penyakit Infeksi Menular Seksual (PIMS) Triwulan I Tahun 2021. Jakarta; 2021.

HIV.gov. Global HIV/AIDS Overview [Internet]. 2021. Available from: https://www.hiv.gov/federal-response/pepfar-global-aids/global-hiv-aids-overview [accessed 2022 Jul 13]

Limalvin NP, Putri WCWS, Sari KAK. Gambaran Dampak Psikologis, Sosial dan Ekonomi pada ODHA di Yayasan Spirit Paramacitta Denpasar. Intisari Sains Medis. 2020;11(1).

Coffin J, Blomberg J, Fan H, Gifford R, Hatziioannou T, Lindemann D, et al, ICTV Report Consortium. ICTV Virus Taxonomy Profile: Retroviridae 2021. J Gen Virol. 2021 Dec;102(12):001712. doi: 10.1099/jgv.0.001712.

Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. 9th ed. Philadelphia: Elsevier; 2021

Riedel S, Morse SA, Mietzner T, Miller S, Hobden JA, Detrick B, et al. Jawetz, Melnick & Adelberg’s. Medical Microbiology. 28th ed. New York: McGraw-Hill Education; 2019

Adhiambo M, Makwaga O, Adungo F, Kimani H, Mulama DH, Korir JC, Mwau M. Human immunodeficiency virus (HIV) type 1 genetic diversity in HIV positive individuals on antiretroviral therapy in a cross-sectional study conducted in Teso, Western Kenya. Pan Afr Med J. 2021 Apr 7;38:335. doi: 10.11604/pamj.2021.38.335.26357.

Gartner MJ, Roche M, Churchill MJ, Gorry PR, Flynn JK. Understanding the mechanisms driving the spread of subtype C HIV-1. EBioMedicine. 2020 Mar;53:102682. doi: 10.1016/j.ebiom.2020.102682.

Abongwa LE, Nyamache AK, Torimiro JN, Okemo P, Charles F. Human immunodeficiency virus type 1 ((HIV-1) subtypes in the northwest region, Cameroon. Virol J. 2019 Aug 15;16(1):103. doi: 10.1186/s12985-019-1209-6.

Fumarola B, Calza S, Renzetti S, El Hamad I, Pezzoli MC, Izzo I, et al. Immunological Evolution of a Cohort of HIV-2 Infected Patients: Peculiarities of an Underestimated Infection. Mediterr J Hematol Infect Dis. 2022 Mar 1;14(1):e2022016. doi: 10.4084/mjhid.2022.016.

Esbjörnsson J, Jansson M, Jespersen S, Månsson F, Hønge BL, Lindman J, et al. HIV-2 as a model to identify a functional HIV cure. AIDS Res Ther. 2019 Sep 5;16(1):24. doi: 10.1186/s12981-019-0239-x.

German Advisory Committee Blood (Arbeitskreis Blut), Subgroup ‘Assessment of Pathogens Transmissible by Blood’. Human Immunodeficiency Virus (HIV). Transfus Med Hemother. 2016 May;43(3):203-22. doi: 10.1159/000445852.

Esbjörnsson J, Månsson F, Kvist A, da Silva ZJ, Andersson S, Fenyö EM, et al; Sweden and Guinea-Bissau Cohort Research Group. Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study. Lancet HIV. 2018 Nov 1:S2352-3018(18)30254-6. doi: 10.1016/S2352-3018(18)30254-6.

Kapoor AK, Padival S. HIV-2. [Updated 2021 Aug 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572083/

Irshad U, Mahdy H, Tonismae T. HIV In Pregnancy. [Updated 2022 Feb 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558972/

Prince PD, Matser A, van Tienen C, Whittle HC, Schim van der Loeff MF. Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis. AIDS. 2014 Feb 20;28(4):549-58. doi: 10.1097/01.SPC.0000432532.87841.78.

Yamaguchi J, Vallari A, McArthur C, et al. Brief Report: Complete Genome Sequence of CG-0018a-01 Establishes HIV-1 Subtype L. J Acquir Immune Defic Syndr. 2020;83(3):319-322. doi:10.1097/QAI.0000000000002246

Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Fleminger I, Kirtley S, et al; WHO–UNAIDS Network for HIV Isolation Characterisation. Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. Lancet Infect Dis. 2019 Feb;19(2):143-155. doi: 10.1016/S1473-3099(18)30647-9.

Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. Curr Opin HIV AIDS. 2019 May;14(3):153-160. doi: 10.1097/COH.0000000000000534.

Giovanetti M, Ciccozzi M, Parolin C, Borsetti A. Molecular Epidemiology of HIV-1 in African Countries: A Comprehensive Overview. Pathogens. 2020;9(12):1072. doi:10.3390/pathogens9121072

Désiré N, Cerutti L, Le Hingrat Q, et al. Characterization update of HIV-1 M subtypes diversity and proposal for subtypes A and D sub-subtypes reclassification. Retrovirology. 2018;15(1):80. doi:10.1186/s12977-018-0461-y

Mendes Da Silva RK, Monteiro de Pina Araujo II, Venegas Maciera K, Gonçalves Morgado M, Lindenmeyer Guimarães M. Genetic Characterization of a New HIV-1 Sub-Subtype A in Cabo Verde, Denominated A8. Viruses. 2021;13(6):1093. doi:10.3390/v13061093

HIV Sequence Database | HIV Circulating Recombinant Forms (CRFs). Update 4 Mar 2022. Available from: https://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html [accessed 2022 July 15]

Khairunisa SQ, Megasari NLA, Ueda S, Budiman W, Kotaki T, Nasronudin, Kameoka M. 2018-2019 Update on the Molecular Epidemiology of HIV-1 in Indonesia. AIDS Res Hum Retroviruses. 2020 Nov;36(11):957-963. doi: 10.1089/AID.2020.0151.

Esparza J, Nitsche A, Damaso CR. Beyond the myths: Novel findings for old paradigms in the history of the smallpox vaccine. PLOS Pathogens. 2018; 14(7): e1007082. https://doi.org/10.1371/journal.ppat.1007082

Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nature reviews Immunology. 2021; 21(2): 83–100. https://doi.org/10.1038/s41577-020-00479-7

Vetter V, Denizer G, Friedland LR, Krishnan J, Shapiro M. (2018). Understanding modern-day vaccines: what you need to know. Annals of medicine. 2018; 50(2): 110–120. https://doi.org/10.1080/07853890.2017.1407035

HHS. Vaccine Types [Internet] Department of Health and Health Service. 2022 [cited 14 July 2022] Available from: https://www.hhs.gov/immunization/basics/types/index.html

Shah N, Faridi MMA, Mitra M, Bavdekar A, Karadkhele A, Puppalwar G, Jain R. Review of long term immunogenicity and tolerability of live hepatitis A vaccine. Hum Vaccin Immunother. 2020; 16(11): 2816-2821. https://doi.org/10.1080/21645515.2020.1741997

Hargrave A, Mustafa AS, Hanif A, Tunio JH, Hanif SNM. Current Status of HIV-1 Vaccines. Vaccines (Basel). 2021;9(9):1026. doi:10.3390/vaccines9091026

Ng'uni T, Chasara C, Ndhlovu ZM. Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions. Front Immunol. 2020;11:590780. doi:10.3389/fimmu.2020.590780

Wu L. HIV Evades Immune Surveillance by Methylation of Viral RNA. Biochemistry. 2019;58(13):1699-1700. doi:10.1021/acs.biochem.9b00152

Dufloo J, Bruel T, Schwartz O. HIV-1 cell-to-cell transmission and broadly neutralizing antibodies. Retrovirology. 2018;15(1):51. doi:10.1186/s12977-018-0434-1

Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 10th ed. Philadelphia: Elsevier; 2022

Esparza J. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine. 2013 Aug 2;31(35):3502-18. doi: 10.1016/j.vaccine.2013.05.018.

Zagury D, Léonard R, Fouchard M, et al. Immunization against AIDS in humans. Nature. 1987 Mar 19-25;326(6110):249-50. doi: 10.1038/326249a0

Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881-1893. doi:10.1016/S0140-6736(08)61591-3

Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study [published correction appears in Lancet Infect Dis. 2011 Jul;11(7):495]. Lancet Infect Dis. 2011;11(7):507-515. doi:10.1016/S1473-3099(11)70098-6

Gray GE, Moodie Z, Metch B, et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis. 2014;14(5):388-396. doi:10.1016/S1473-3099(14)70020-9

Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013;369(22):2083-2092. doi:10.1056/NEJMoa1310566

Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005 Mar 1;191(5):654-65. doi: 10.1086/428404.

Pitisuttithum P, Gilbert P, Gurwith M, et al; Bangkok Vaccine Evaluation Group. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006 Dec 15;194(12):1661-71. doi: 10.1086/508748.

Gray GE, Bekker LG, Laher F, et al. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. N Engl J Med. 2021;384(12):1089-1100. doi:10.1056/NEJMoa2031499

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492.

Global Advocacy for HIV Prevention. Trial search. Available from: https://www.avac.org/trial-search?field_prevention_option_tid%5B%5D=1&keys=&title=&field_status_value=All&field_phase_value=All [accessed 2022 Jul 16]

Zolla-Pazner S, deCamp A, Gilbert PB, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One. 2014;9(2):e87572. doi:10.1371/journal.pone.0087572

Venkatesan P. Preliminary phase 1 results from an HIV vaccine candidate trial. Lancet Microbe. 2021 Mar;2(3):e95. doi: 10.1016/S2666-5247(21)00042-2.

Hosseinipour MC, Innes C, Naidoo S, et al. Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. Clin Infect Dis. 2021;72(1):50-60. doi:10.1093/cid/ciz1239

National AIDS Treatment and Advocacy Program. Phase 2b Efficacy Trial of Mosaic HIV-1 Vaccine Regimen in African Women (Imbokodo). Available from: https://www.natap.org/2022/CROI/croi_159a.htm [accessed 2022 Jul 17]

Diterbitkan

2022-12-01

Cara Mengutip

Balatif, R., Harahap, F. H., & Almira, I. D. (2022). Recent Development on HIV Variants and HIV Vaccine. Cermin Dunia Kedokteran, 49(12), 687–692. https://doi.org/10.55175/cdk.v49i12.328

Terbitan

Bagian

Articles